Zalifrelimab 产品活性：Zalifrelimab (AGEN1884) 是一种靶向 CTLA-4 (CTLA-4) 的全人 IgG1 单克隆抗体。Zalifrelimab 拮抗受 CTLA-4 信号调节的免疫细胞激活的抑制性检查点。 产品来源： https://www.medchemexpress.cn/zalifrelimab.html 研究领域：Immunology/Inflammation 作用靶点：CTLA-4 In Vitro: Zalifrelimab (AGEN1884; 0.1, 1, 10 or 100 μg/mL) potently enhances antigen-specific T cell responsiveness that could be potentiated in combination with other immunomodulatory antibodies. Zalifrelimab combined effectively with PD-1 blockade to elicit a T cell proliferative response in the periphery. In Vivo: Zalifrelimab (AGEN1884; 10 mg/kg; i.v.; on days 1 and 29) is well-tolerated in non-human primates and enhances vaccine-mediated antigen-specific immunity. 相关产品：Ipilimumab | Abatacept | Tremelimumab | Anti-Mouse CTLA-4 Antibody (9D9) | Botensilimab | Vudalimab | Gotistobart | Nurulimab | Davoceticept | Firastotug | Lorigerlimab | Muzastotug | Quavonlimab | Sovipostobart | Tuvonralimab 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。